Quanterix to Convene Leading Industry Researchers at Alzheimer’s Association International Conference 2019 Following Closin...
July 11 2019 - 1:30PM
Business Wire
Continued growth in 2019 marked by new HD-X
product launch, acquisition of the leading neurofilament light
(Nf-L) antibody supplier, new corporate headquarters and new
ground-breaking neurodegenerative research proving the utility of
digital biomarkers across a spectrum of chronic conditions
Quanterix Corporation (NASDAQ: QTRX), a company digitizing
biomarker analysis with the goal of advancing the science of
precision health, marks the end of the first half of 2019 with
major milestones as it continues to expand its footprint in
neurology and lead the digital biomarker revolution across
healthcare. Most recently, on July 1, Quanterix announced it had
closed its acquisition of UmanDiagnostics AB, a company widely
recognized as the leading provider of antibodies to measure
Nf-L.
“Quanterix has realized significant growth attributable to our
new technological inovations and company expansions, but also from
a growing consensus that biomarkers can transform healthcare,” said
Kevin Hrusovsky, Chief Executive Officer, President and Chairman of
Quanterix. “Specifically, with Nf-L, there is a growing body of
evidence that supports the use of this biomarker as a potential
surrogate secondary endpoint in multiple sclerosis (MS) and a
co-primary endpoint in traumatic brain injury (TBI) drug trials,
and as a promising early indicator of Alzheimer’s disease
progression. It is becoming increasingly promising that the ability
to measure Nf-L in blood is a significant advance in the diagnosis
and monitoring of a wide range of neurodegenerative conditions and
could have a profound impact measuring neurological health, which
is one of the reasons that we are excited about our acquisition of
Uman.”
Quanterix first announced its definitive agreement to acquire
privately held Uman on June 26. Based in Umeå, Sweden, Uman has
become the provider of choice for biopharmaceutical and diagnostic
applications. The acquisition allows Quanterix to supply
researchers globally with the “best-in-class” Simoa Nf-L assays,
while continuing to innovate new digital biomarkers to advance the
field of research in diagnostics for neurological disorders. The
deal also positions Quanterix to capitalize on the growth fueled by
the momentum in Nf-L as a tremendously promising brain biomarker.
Publications citing the Simoa Nf-L assay have accelerated since the
assay was launched in 2016 and totaled 172 as of the end of 2018,
adding to nearly 400 publications on Uman’s Nf-L antibodies in
Cerebrospinal Fluid (CSF).
“Nf-L has seen strong growth in the last three years since we
developed the first assay using Uman’s antibodies that reliably
measures Nf-L in blood, and many of the world’s foremost neurology
researchers and clinicians believe that Nf-L may be the most
clinically relevant brain biomarker available today,” continued
Hrusovsky. “The unique specificity of Uman’s antibodies combined
with the exquisite sensitivity of Quanterix’ Simoa platforms
enables the world’s most sensitive assay for measuring Nf-L in
blood.”
The impact of Quanterix’ strategic investments and milestones as
they specifically support Alzheimer’s research will be on full
display at the Alzheimer’s Association International Conference
(AAIC), the largest and most influential international meeting
dedicated to dementia science, taking place July 14-18 in Los
Angeles, Calif. On July 15, Hrusovsky will provide an update on
Quanterix' progress and plans for fueling neuro biomarker
innovations and will moderate a panel discussion featuring several
of the world’s foremost researchers in Alzheimer’s disease. To
learn more about the event, and to request an invitation, email
info@quanterix.com. To meet with Quanterix and learn more about how
the company is disrupting Alzheimer’s research, visit Booth #526
during the conference exhibit.
Earlier in June, the company re-engineered ultra-sensitivity
with the launch of the Simoa HD-X Analyzer, its latest fully
automated Simoa bead-based immunoassay instrument model. The HD-X
is the next generation HD-1, launched in 2013, which first made
Simoa’s ultrasensitive digital biomarker measurements available to
researchers around the world and which has led to over 500
peer-reviewed publications. The ground-breaking HD-X leverages many
decades of collective technical expertise and user experiences to
deliver the “best-in-class” technological innovation into practical
reality for researchers. The new flagship HD-X has been designed to
deliver productivity improvements, greater user flexibility,
unparalleled sensitivity, and "best-in-class" assay performance
across a broad assay menu to empower biomarker research and
accelerate drug development.
The acquisition and product launch come on the heels of the
company’s relocation to its new state-of-the-art headquarters in
Billerica, Mass. Buoyed by Quanterix’ rapid growth, the move unites
its CLIA-certified laboratory with its expanding workforce to
accelerate entry into pharmaceutical drug services and further
increase its impact on the transformation of precision healthcare.
The two-story, 92,000 square-foot space features new offices and
expanded manufacturing and laboratory space. By bringing all
business operations together under the same roof as its
CLIA-certified lab and Accelerator Lab providing services to
Biopharma, Quanterix is able to offer customers a single home for
all of its biomarker research needs across a wide range of
therapeutic categories.
The company also announced in June that it had raised nearly
$50M through its ATM facility, which provides the company with
additional capital to support its investments in innovation and
continued growth.
About Quanterix Quanterix is a company that’s digitizing
biomarker analysis with the goal of advancing the science of
precision health. The company’s digital health solution, Simoa, has
the potential to change the way in which healthcare is provided
today by giving researchers the ability to closely examine the
continuum from health to disease. Quanterix’ technology is designed
to enable much earlier disease detection, better prognoses and
enhanced treatment methods to improve the quality of life and
longevity of the population for generations to come. The technology
is currently being used for research applications in several
therapeutic areas, including oncology, neurology, cardiology,
inflammation and infectious disease. The company was established in
2007 and is located in Billerica, Massachusetts. For additional
Information, please visit: https://www.quanterix.com.
Forward-Looking Statements This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as "may,"
"will," "expect," "plan," "anticipate," "estimate," "intend" and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
intended to identify forward-looking statements. Forward-looking
statements in this news release are based on Quanterix’
expectations and assumptions as of the date of this press release.
Each of these forward-looking statements involves risks and
uncertainties. Factors that may cause Quanterix’ actual results to
differ from those expressed or implied in the forward-looking
statements in this press release are discussed in Quanterix’
filings with the U.S. Securities and Exchange Commission, including
the "Risk Factors" sections contained therein. Except as required
by law, Quanterix assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190711005698/en/
Lindsay Sharifipour PAN Communications 617-502-4300
quanterix@pancomm.com
Quanterix (NASDAQ:QTRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Quanterix (NASDAQ:QTRX)
Historical Stock Chart
From Sep 2023 to Sep 2024